Skip to main content
SpringerLink
Log in

Regulation of bone turnover and prevention of bone atrophy in ovariectomized beagle dogs by the administration of 24R, 25(OH)2D3

  • Laboratory Investigations
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Summary

In order to determine whether the administration of 24R,25(OH)2D3 had any beneficial effect on the regulation of bone turnover and the prevention of bone atrophy, we examined beagles for 31 months after ovariectomy (OVX). Fourteen beagle dogs (8.54±1.22 kg body wt-b.w.) were divided into four groups. Group 1 (n=3) was the sham, and Group 2 (n=3) served as the OVX control. In Group 3 (n=4) and Group 4 (n=4), 24,25-dihydroxyvitamin D3(24R,25(OH)2D3) was given daily at dose levels of 2 and 10 mcg/kg B.W., respectively. In Group 4, the dose level was increased to 100 mcg/kg by 17 months. During the experiments, urinary hydroxyproline (U-HPr), serum chemistry, serum bone gla-protein (BGP), and vitamin D metabolite levels were monitored. At the end of the experiment, bone mineral content (BMC) in the 6th and 7th lumbar vertebrae and right femur was determined by single photon absorptiometry. The left iliac bone sample was obtained after tetracycline labeling, and undecalcified sections were observed. In Group 2, excretion of U-HPr increased after OVX and had reached a level of approximately twice the baseline values by 10 months; then it gradually came down to the original level. In Group 3, however, U-HPr excretion remained at the same level as the baseline value, as it did in Group 1. In Group 4, it was remarkably reduced down to 50–60% of the baseline values. Serum BGP level was markedly reduced in Group 4. Serum 24,25(OH)2D levels were markedly increased in Groups 3 and 4. BMC levels of both vertebrae and epi-metaphyseal regions in the femur showed a significant reduction of approximately 25% in Group 2. In Groups 3 and 4, however, they remained at the same level as in Group 1. Histomorphometrical data showed a reduction in the parameters of osteoblast functions in Group 2. In Group 3, both kinetic and static parameters maintained the same level as in Group 1. In Group 4, eroded surface and osteoclast number decreased significantly, but mineral appositional rate and wall thickness maintained the same level as in Group 1. From these findings, it was concluded that, in beagle dogs, the administration of 24R,25(OH)2D3 inhibited the increase of bone turnover and prevented the reduction of cancellous bone mass after a long time postovariectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brommage R, Jarnagin K, DeLuca HF, Yamada S, Takayama H (1983) T-But not 24-hydroxylation of vitamin D is required for skeletal mineralization in rats. Am J Physiol 244:E298-E304

    Google Scholar 

  2. Rothstein M, Olgaard K, Arbelaez M, Finco D, Klahr S, Slatopolosky E (1983) Lack of influence of 24,25-dihydroxy-vitamin D3 on parathyroid hormone secretion from normal or hyperplastic glands. Calcif Tissue Int 35:449–454

    Google Scholar 

  3. Riis BJ, Thomsen K, Christiansen C (1986) Does 24R,25(OH)2-vitamin D3 prevent postmenopausal bone loss? Calcif Tissue Int 34:128–132

    Google Scholar 

  4. Harvey JA, Zerwekh JE, Sakhaee K, Pak CYG (1989) Lack of effect on 24,25-dihydroxyvitamin D3 administration on parameters of calcium metabolism. J Clin Endocrinol Metab 69:467–469

    Google Scholar 

  5. Kappaelle JW, Raymakers JA, Bosch R, Duurma SA (1989) No short-term effects of 24,25-dihydroxycholecalciferol in healthy subjects. Bone 10:397–399

    Google Scholar 

  6. Canterbury JM, Lerman S, Claflin AJ, Henry H, Norman A (1978) Inhibition of parathyroid hormone secretion by 25-hydroxy-cholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest 65:1375–1383

    Google Scholar 

  7. Pavlovitch JH, Cournot-Witmer G, Bourdeau A, Balsan S, Fishcer JA, Heynen G (1981) Suppressive effects of 24,25-dihydroxycholecalciferol on bone resorption induced by acute bilateral nephrectomy in rats. J Clin Invest 68:803–810

    Google Scholar 

  8. Dunstan CR, Hills E, Norman AW, Bishop JE, Mayer E, Wong SYP, Eade Y, Johnson JR, George CRP, Collett P, Kalowski S, Wyndham RN, Lowrence JR, Alfrey AC, Evan RA (1985) Treatment of hemodialysis bone disease with 24,25(OH)2D3 and 1,25-(OH)2D3 alone or in combination. Miner Electrolyte Metab 11:358–368

    Google Scholar 

  9. Tam CS, Heersche JNM, Jones G, Murray TM, Rasmussen H (1986) The effect of vitamin D on bone in vivo. Endocrinology 118:2217–2224

    Google Scholar 

  10. Nakamura T, Kurokawa T, Orimo H (1988) Increase of bone volume in vitamin D-repleted rats by massive administration of 24R,25(OH)2D3. Calcif Tissue Int 43:235–243

    Google Scholar 

  11. Nakamura T, Kurokawa T, Orimo H (in press) Increased bone volume and reduced bone turnover in vitamin D-replete rabbits by the administration of 24R,25-dihydroxyvitamin D3. Bone

  12. Nakamura T, Kurokawa T, Orimo H (1989) Increased mechanical strength of the vitamin D-replete rat femur by the treatment with a large dose of 24R,25(OH)2D3. Bone 10:117–123

    Google Scholar 

  13. Nakamura T, Kurokawa T, Orimo H (in press) Osteonal remodcling and mechanical properties of the femoral cortex in rabbits treated with 24R,25(OH)2D3. Calcif Tissue Int

  14. Yamato H, Matsumoto T, Fukumoto S, Ikeda K, Ishizuka S, Ogata E (1989) Effects of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3) metabolism in vitamin D-deficient rats infused with 1,25(OH)2D3. Endocrinology 124:511–517

    Google Scholar 

  15. Hardt AB, Jee WSS (1982) Trabecular bone structural variation in biopsy sites of the beagle ilium. Calcif Tissue Int 34:391–395

    Google Scholar 

  16. Faugere MC, Friedler RM, Fanti P, Malluche HH (1990) Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study employing sequential biopsies. J Bone Miner Res 5:263–272

    Google Scholar 

  17. Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M (1983) Relationships between surface, volume and thickness of iliac bone in aging and in osteoporosis. J Clin Invest 72:1396–1409

    Google Scholar 

  18. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche HH, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595–610

    Google Scholar 

  19. Boyce RW, Franks AF, Jankowsky ML, Orcutt CM, Piacquadio AM, White JM, Beven JA (1990) Sequential histomorphometric changes in cancellous bone from ovario-hysterectomized dogs. J Bone Miner Res 5:947–953

    Google Scholar 

  20. dannucci GA, Martin RB, Patterson-Buckendahl P (1987) Ovariectomy and trabecular bone remodeling in the dog. Calcif Tissue Int 40:194–199

    Google Scholar 

  21. Snow GR, Cook MA, Anderson C (1984) Oophorectomy and cortical bone remodeling in the beagle. Calcif Tissue Int 36:586–590

    Google Scholar 

  22. Malluche HH, Faugere MC, Rush M, Friedler RM (1986) Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function in experimental beagle dogs. Endocrinology. 119:2649–2654

    Google Scholar 

  23. Martin RB, Butcher RL, Sherwood LL, Buckendahl P, Boyd RD, Farris D, Sharkey N, Dannucci G (1987) Effects of ovariectomy in beagle dogs. Bone 8:23–31

    Google Scholar 

  24. National Academy of Sciences, Subcommittee on Dog Nutrition (1975) Nutrient requirements of dogs, 1974 revised edition: calcium and phosphorus, pp 18–19

  25. Wientroub S, Price PA, Reddi AH (1987) The dichotomy in the effects of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxy-vitamin D3 on bone gammacarboxyglutamic acid-containing protein in serum and bone in vitamin D-deficient rats. Calcif Tissue Int 40:166–172

    Google Scholar 

  26. Endo H, Kiyoki M, Kawashima K, Naruchi T, Hashimoto Y (1980) Vitamin D3 metabolites and PTH synergistically stimulate bone formation of chick embryonic femur in vitro. Nature 286:262–264

    Google Scholar 

  27. Ornoy A, Goodwin D, Noff D, Edelstein S (1978) 24,25-Dihydroxyvitamin D is a metabolite of vitamin D essential for bone formation. Nature 276:517–519

    Google Scholar 

  28. Malluche HH, Faugere MC, Friedler RM, Fanti P (1988) 1,25-Dihydroxyvitamin D3 corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. Endocrinology 122:1998–2006

    Google Scholar 

  29. Gordeladze JO, Mortensen B, Nordal K, Halse J, Dahl E, Aksnes L, Gautvik KM (1987) The effect of parathyroid hormone (PTH) and 24,25-dihydroxy-vitamin D3 on adenyl cyclase of iliac crest biopsies: diagnostic and prognostic tool for evaluation and treatment of uremic patients. Scand J Clin Lab Invest 47(suppl 186):13–20

    Google Scholar 

  30. Mahgoub A (1981) Interaction between 24R,25-dihydroxycholecalciferol and 1,25-dihydroxycholecalciferol on 45Ca release from bone in vitro. Calcif Tissue Int 33:663–666

    Google Scholar 

  31. Yamato H, Okazaki R, Matsumoto T, Akaogi K, Taniguchi N, Kumegawa M, Ogata E (1990) Effect of 24,25-dihydroxyvitamin D3 on the formation of osteoclast-like cells from hemopoietic blast cells. J Bone Miner Res 5:S83

    Google Scholar 

  32. Minghetti PP, Norman AW (1988) 1,25(OH)2-vitamin D3 receptors: gene regulation and genetic circuitry. FASEB J 1:3043–3053

    Google Scholar 

  33. Thomsen K, Riis B, Christiansen C (1986) Effect of estrogen/gestagen and 24R,25-dihydroxyvitamin D3 therapy on bone formation in postmenopausal women. J Bone Miner Res 1:503–507

    Google Scholar 

  34. Reeve J, Tellez M, Green JR, Russell RGG, Mawer EB, Meunier PJ (1982) Long-term treatment of osteoporosis with 24,25-dihydroxycholecalciferol. Acta Endocrinol 101:636–640

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Faculty of Medicine, University of Occupational and Environmental Health, 1-l Iseigaoka, Yawatanishi-ku, 807, Kitakyushu, Japan

    Toshitaka Nakamura & Katsumi Suzuki

  2. Kureha Chemical Industry, 3-26-2, Hyakunin-cho Shinjuku-ku, 113, Tokyo, Japan

    Yumiko Nagai & Hideyuki Yamato

  3. Department of Geriatrics, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113, Tokyo, Japan

    Hajime Orimo

Authors
  1. Toshitaka Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yumiko Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideyuki Yamato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katsumi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hajime Orimo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, T., Nagai, Y., Yamato, H. et al. Regulation of bone turnover and prevention of bone atrophy in ovariectomized beagle dogs by the administration of 24R, 25(OH)2D3 . Calcif Tissue Int 50, 221–227 (1992). https://doi.org/10.1007/BF00296286

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00296286

Key words

Search

Navigation